Replies to post #249551 on Biotech Values

[vinmantoo]

Thanks dewophile.

In the Phase 2b B-Clear study (209668), bepirovirsen (BPV; an antisense oligonucleotide) 300 mg for 24 weeks (wks) achieved sustained HBsAg and HBV DNA loss (

Looks like duration for some patients isn't very good. They should be told to use a different approach. Perhaps a call to ENTA would help.

[dewophile]

These data came up today in the GSK presentation and the cc. They confirmed interferon does not add significant efficacy to Bepirovirsen monotherapy
They are hoping adding the JNJ siRNA drug will increase efficacy or at least bring more patients into the low surface antigen range to enable more patients to be eligible for Bepi